GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated September 24, 2024, serves as a transaction notification for Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The report covers share purchase transactions executed on September 20, 2024, and September 23, 2024.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific equity transactions by directors.
Material Changes and Transaction Details
The filing reports the following purchases of GSK securities by Independent Non-Executive Directors and the Senior Independent Non-Executive Director:
- Wendy Becker: Purchased 463 Ordinary Shares at £15.5650 each on September 20, 2024, on the London Stock Exchange.
- Elizabeth (Liz) McKee Anderson: Purchased 223 American Depositary Shares (ADSs) at $41.0114 each on September 23, 2024, on the New York Stock Exchange.
- Charles Bancroft: Purchased 1,801 ADSs at $41.0114 each on September 23, 2024, on the New York Stock Exchange.
- Dr. Hal Barron: Purchased 224 ADSs at $41.0114 each on September 23, 2024, on the New York Stock Exchange.
- Dr. Anne Beal: Purchased 224 ADSs at $41.0114 each on September 23, 2024, on the New York Stock Exchange.
- Dr. Hal Dietz: Purchased 224 ADSs at $41.0114 each on September 23, 2024, on the New York Stock Exchange.
- Dr. Jesse Goodman: Purchased 224 ADSs at $41.0114 each on September 23, 2024, on the New York Stock Exchange.
- Dr. Jeannie Lee: Purchased 224 ADSs at $41.0114 each on September 23, 2024, on the New York Stock Exchange.
- Dr. Vishal Sikka: Purchased 773 ADSs at $41.0114 each on September 23, 2024, on the New York Stock Exchange.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of insider trading activity.
Key Facts for Investor Verification
- Multiple directors executed share purchases on the same day (September 23, 2024) at an identical price of $41.0114 per ADS.
- Transactions were conducted on both the London Stock Exchange (Ordinary Shares) and the New York Stock Exchange (ADSs).
- All reported transactions were purchases, indicating no insider selling activity during this specific reporting window.
- The filing does not disclose the total aggregate holdings of these directors post-transaction.